301 CARLSON PARKWAY, MINNEAPOLIS, MN
Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Voting Results from Diamedica Therapeutics Inc. Shareholder Meeting
Reports First Quarter 2026 Financial Results and Provides Business Highlights
Annual Report to Security Holders
Financial Results, Press Release
Other Events
Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus Filed Pursuant to Rule 424(b)(2)
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload